Abstract: The available delivery capability (ADC) of a power distribution network with respect to a power transaction is evaluated in real-time. The power transaction involves simultaneous power deliveries from power sources in a source area to loads in a sink area. First, a list of contingencies are ranked in the power distribution network with respect to static security constraints to obtain a subset of top-ranked contingencies. For each top-ranked contingency in the subset, a representation of the power transaction in a steady state of the power distribution network, in a form of parameterized three-phase power flow equations, is solved to obtain a corresponding power delivery capability (PDC) and a corresponding binding constraint among the static security constraints. The reliability of the power transaction in the power distribution network is then evaluated based on, at least in part, a first contingency PDC which is a smallest PDC among obtained corresponding PDCs.

Abstract: Techniques and mechanisms to mitigate fixed pattern noise in image sensor data. In an embodiment, readout circuitry includes an adaptive analog-to-digital converter (ADC) comprising a differential amplifier and a feedback path coupled across the differential amplifier, where the ADC is to receive a ramp signal, a control signal associated with a transition rate of the ramp signal, and an analog signal generated by one or more pixels. In another embodiment, the feedback path and/or one or more other circuit elements coupled to the differential amplifier are configured, based on the control signal, to provide one of multiple loop gains with the differential amplifier. The ADC provides a digital output to determine a comparison based on the ramp signal and the analog signal.

Abstract: Disclosed are various embodiments for identifying relevant topics for an item from search queries. Search queries are obtained from users to search a collection of user reviews for a specific item. Relevant topics for the specific item are identified by analyzing the queries. A user interface is generated based at least in part on at least some of the relevant topics.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: Relevant topics for an item may be extracted from customer review search queries. Customer review search queries are obtained from customers to search a collection of customer reviews for a specific item. Relevant topics for the specific item are extracted by analyzing the queries. A user interface is generated based at least in part on at least some of the relevant topics.

Abstract: Techniques and mechanisms to mitigate fixed pattern noise in image sensor data. In an embodiment, readout circuitry includes an adaptive analog-to-digital converter (ADC) comprising a differential amplifier and a feedback path coupled across the differential amplifier, where the ADC is to receive a ramp signal, a control signal associated with a transition rate of the ramp signal, and an analog signal generated by one or more pixels. In another embodiment, the feedback path and/or one or more other circuit elements coupled to the differential amplifier are configured, based on the control signal, to provide one of multiple loop gains with the differential amplifier. The ADC provides a digital output to determine a comparison based on the ramp signal and the analog signal.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: An apparatus and method for detecting an intensity of radiation in a process chamber, such as an ultraviolet curing process chamber, is disclosed. An exemplary apparatus includes a process chamber having a radiation source therein, wherein the radiation source is configured to emit radiation within the process chamber; a radiation sensor attached to the process chamber; and an optical fiber coupled with the radiation source and the radiation sensor, wherein the optical fiber is configured to transmit a portion of the emitted radiation to the radiation sensor, and the radiation sensor is configured to detect an intensity of the portion of the emitted radiation via the optical fiber.

Abstract: A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.

Abstract: The present invention discloses a cooling fetch apparatus of performs, and the apparatus includes: a first fetch mechanism, moved back and forth, for fetching each perform formed in a mold of an injection molding machine from the mold; a second fetch mechanism, moved back and forth, for fetching each preform on the first fetch mechanism. After the second fetch mechanism fetches a predetermined quantity of performs, the performs on second fetch mechanism are unloaded sequentially, such that the injection molding process and the cooling process of the performs are separated. The timing of fetching each perform on the second fetch mechanism is controlled for assuring a good cooling effect of each preform.

Abstract: The present invention discloses a cooling fetch method of preforms, and the method includes: using a first fetch mechanism for fetching each preform formed in a mold of an injection molding machine from the mold; a second fetch mechanism for fetching each preform on the first fetch mechanism. After the second fetch mechanism fetches a predetermined quantity of preforms, the preforms on second fetch mechanism are unloaded sequentially, such that the injection molding process and the cooling process of the preforms are separated. The timing of fetching each preform on the second fetch mechanism is controlled for assuring a good cooling effect of each preform.

Abstract: The present invention discloses a cooling fetch apparatus of performs, and the apparatus includes: a first fetch mechanism, moved back and forth, for fetching each perform formed in a mold of an injection molding machine from the mold; a second fetch mechanism, moved back and forth, for fetching each preform on the first fetch mechanism. After the second fetch mechanism fetches a predetermined quantity of performs, the performs on second fetch mechanism are unloaded sequentially, such that the injection molding process and the cooling process of the performs are separated. The timing of fetching each perform on the second fetch mechanism is controlled for assuring a good cooling effect of each preform.

Abstract: The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.

Abstract: The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which includes PVP and solid PEG etc.

Abstract: The present invention relates to novel anhydrous amorphous forms of bis[(E)[4-(4-fluorophenyl)isopropyl[methyl(methylsulfonyl)amino]pyrimidinyl](3R,5S)-3,5-dihydroxyhept enoic acid]calcium salt (rosuvastatin calcium), (±)7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)3,5-dihydroxy heptenoic acid monosodium salt (fluvastatin sodium) and bis[(E)-3,5-dihydroxy-7-[4?-(4?-fluorophenyl)-2?-cyclopropyl-quinolin-3?-hept-6-enoic acid]calcium salt (pitavastatin calcium), to processes for their preparation, to pharmaceutical compositions containing them and to methods of treatment using the same. The rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium obtained are known valuable agents useful in treating hyperlipidemia and hypercholestrolemia.

Abstract: The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which includes PVP and solid PEG etc.

Abstract: The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.